Your session is about to expire
← Back to Search
Stem Cell Transplantation for Leukemia
Study Summary
This trial is for cancer patients who need a peripheral blood stem cell transplant. The study is testing how well a selective removal of naïve T cells works in preventing GVHD after the transplant.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 3 trial • 87 Patients • NCT00075478Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am a candidate for a stem cell transplant and have a specific type of blood cancer.I do not have uncontrolled infections, severe organ problems, HIV, or fall outside the weight limits.My kidney, heart, lung, and liver functions meet the required levels.My kidney, heart, lung, and liver functions meet the required levels.My donor is 18 or older, matches my HLA, and agrees to donate stem cells.I have a donor match willing to donate stem cells.I have a donor who matches my HLA type for a stem cell donation.I am under 50 and eligible for high-intensity treatment or between 50-60 for lower intensity.
- Group 1: Arm D (MUD)
- Group 2: Arm B (MRD)
- Group 3: Arm A (MRD)
- Group 4: Arm C (MUD)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any other case studies concerning Peripheral Blood Stem Cell Transplantation that have been reported?
"City of Hope Comprehensive Cancer Center was the first to conduct research into Peripheral Blood Stem Cell Transplantation in 1997. As of now, 2783 clinical trials have been completed, with 1129 actively being conducted across various sites - particularly Pittsburgh Pennsylvania."
In what instances has Peripheral Blood Stem Cell Transplantation been found to be beneficial?
"Peripheral Blood Stem Cell Transplantation is a common treatment option for small cell lung cancer (SCLC) and can often be effective in addressing certain forms of dermatitis, atopy, acute leukemia, multiple sclerosis and many other conditions."
How many individuals is the trial accepting at this time?
"Unfortunately, this clinical study is no longer open for recruitment. It was first posted on February 3rd 2015 and the latest update was made June 28th 2022. For those searching for other trials, there are currently 3776 studies admitting patients with acute biphenotypic leukemia and 1129 studies looking to recruit participants for Peripheral Blood Stem Cell Transplantation."
What potential risks should be considered regarding Peripheral Blood Stem Cell Transplantation?
"Peripheral Blood Stem Cell Transplantation has been assessed as a 2 on our safety scale, due to existing data demonstrating its safety but an absence of evidence in support of efficacy."
Are there remaining opportunities for potential participants to join this experiment?
"Confirmed. As reported on clinicaltrials.gov, this research study is not presently recruiting participants despite having been posted in February 2015 and updated as recently as June 28th 2022. Alternatively, 4,905 other medical trials are actively seeking volunteers at the present time."
Share this study with friends
Copy Link
Messenger